Live Analyst Rating Changes 36053 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Richard Law CFA
GS

Richard Law CFA

Goldman Sachs
Wall Street Analyst
★★★☆☆
#1905
on 13Foresight · ranked by our own returns
51%
Success Rate
+3.4%
Average Return
21 of 41 calls profitable · -4.6% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 51% of Richard Law CFA's ratings turned a profit when each position was held for 1 year — averaging +3.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 19 Hold 7 Sell
Richard's Stock Coverage 22 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
VKTX
Viking Therapeutics
 Sep 22, 2026 HOLD Strong Buy
+126.4% avg upside
31 analysts
$38.00
19.49% Upside
 -20.2% ·
CLDX
Celldex
 Sep 22, 2026 HOLD Strong Buy
+33.8% avg upside
28 analysts
$28.00
11.50% Downside
 -3.3% ·
OLMA
Olema Pharmaceuticals
 Sep 14, 2026 BUY Strong Buy
+306.9% avg upside
16 analysts
$18.00
110.86% Upside
 -16.0% ·
PTGX
Protagonist Therapeutics
 Aug 31, 2026 BUY Strong Buy
-14.9% avg upside
19 analysts
$186.00
32.04% Upside
 -4.9% ·
VRDN
Viridian Therapeutics
 Aug 19, 2026 BUY Strong Buy
+74.7% avg upside
32 analysts
$40.00
100.06% Upside
 -17.5% ·
MLYS
Mineralys Therapeutics, Inc.
 Aug 12, 2026 BUY Strong Buy
+82.1% avg upside
12 analysts
$40.00
63.31% Upside
 -5.2% ·
BCAX
Bicara Therapeutics Inc.
 Aug 11, 2026 HOLD Strong Buy
+76.3% avg upside
16 analysts
$20.00
7.80% Upside
 -19.1% ·
RCUS
Arcus Biosciences
 Aug 10, 2026 BUY Strong Buy
+38.6% avg upside
21 analysts
$42.00
63.77% Upside
 -12.9% ·
SLN
Silence Therapeutics
 Jul 27, 2026 SELL Strong Buy
+220.9% avg upside
10 analysts
$4.00
62.94% Downside
 +7.2% ·
COAG
Hemab Therapeutics Holdings, Inc.
 Jul 13, 2026 BUY Strong Buy
+64.2% avg upside
5 analysts
$46.00
41.12% Upside
 -21.2% ·
MLTX
MoonLake Immunotherapeutics
 May 11, 2026 SELL Strong Buy
+154.7% avg upside
20 analysts
$12.00
4.83% Upside
 +36.1% ·
RCKT
Rocket Pharmaceuticals
 Mar 27, 2026 SELL Buy
+524.3% avg upside
30 analysts
$3.00
15.75% Upside
 +31.2% ·
ARQT
Arcutis Biotherapeutics
 Feb 27, 2026 HOLD Strong Buy
+50.6% avg upside
14 analysts
$33.00
23.34% Upside
 +1.3% ·
QTTB
Q32 Bio
 Aug 15, 2023 HOLD Strong Buy
+489.3% avg upside
28 analysts
$30.60
221.00% Upside
 +69.8% ·
BEAM
Beam Therapeutics
 Aug 09, 2023 HOLD Strong Buy
+111.8% avg upside
25 analysts
$47.00
91.66% Upside
 -6.3% ·
CRSP
Crispr Therapeutics AG
 Aug 08, 2023 HOLD Buy
+35.4% avg upside
41 analysts
$63.00
12.53% Upside
 -9.8% ·
KYMR
Kymera Therapeutics
 Aug 04, 2023 HOLD Strong Buy
-0.1% avg upside
37 analysts
$37.00
66.46% Downside
 +86.3% ·
NTLA
Intellia Therapeutics
 Jun 13, 2023 BUY Buy
+215.8% avg upside
37 analysts
$76.00
531.79% Upside
 -43.6% ·
GLUE
Monte Rosa Therapeutics
 May 12, 2023 HOLD Strong Buy
+94.3% avg upside
15 analysts
$11.00
6.29% Downside
 -14.6% ·
EDIT
Editas Medicine
 May 05, 2023 HOLD Buy
+413.5% avg upside
33 analysts
$14.00
440.54% Upside
 -42.0% ·
ARVN
Arvinas Holding Company
 May 05, 2023 BUY Buy
+279.3% avg upside
28 analysts
$61.00
713.34% Upside
 +29.7% ·
CCCC
C4 Therapeutics
 Feb 24, 2023 HOLD Strong Buy
+466.4% avg upside
19 analysts
$10.00
219.45% Upside
 +68.7% ·
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Richard Law CFA — Frequently Asked Questions
How accurate are Richard Law CFA's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Richard's ratings were profitable over a one-year hold, with an average return of +3.6% per rating, or -4.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Richard ranked on 13Foresight?
Richard Law CFA is currently ranked #1905 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Richard cover?
Richard most recently has ratings on VKTX, CLDX, OLMA, PTGX, VRDN, MLYS, BCAX, RCUS, SLN, COAG, MLTX, RCKT and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.